Page last updated: 2024-08-21

treosulfan and Diffuse Mixed Small and Large Cell Lymphoma

treosulfan has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Crodel, CC; Frietsch, JJ; Hilgendorf, I; Hochhaus, A; Linke, P; Miethke, J; Schnetzke, U; Scholl, S	1
Balleisen, L; Basara, N; Behre, G; Casper, J; Christopeit, M; Ganser, A; Hinke, A; Hinke, R; Kahl, C; Koenigsmann, M; Metzner, B; Mohren, M; Niederwieser, D; Reichle, A; Sayer, HG; Stadler, M; Theurich, S; Uharek, L	1
Casper, J; Dölken, G; Freund, M; Hammer, U; Hartung, G; Kiefer, T; Kleine, HD; Knauf, W; Knopp, A; Steiner, B; Wegener, R; Wilhelm, S; Wolff, D	1

Trials

2 trial(s) available for treosulfan and Diffuse Mixed Small and Large Cell Lymphoma

Article	Year
Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial. Bone marrow transplantation, 2014, Volume: 49, Issue:3 Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Disease Progression; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Prospective Studies; Recurrence; Risk Factors; Rituximab; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Young Adult	2014
Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood, 2004, Jan-15, Volume: 103, Issue:2 Topics: Acute Disease; Adult; Aged; Alkylating Agents; Busulfan; Chronic Disease; Family; Female; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukemia; Living Donors; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2004

Article

Year

Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial.

Bone marrow transplantation, 2014, Volume: 49, Issue:3

Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Disease Progression; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Prospective Studies; Recurrence; Risk Factors; Rituximab; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Young Adult

2014

Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.

Blood, 2004, Jan-15, Volume: 103, Issue:2

Topics: Acute Disease; Adult; Aged; Alkylating Agents; Busulfan; Chronic Disease; Family; Female; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukemia; Living Donors; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2004

Other Studies

1 other study(ies) available for treosulfan and Diffuse Mixed Small and Large Cell Lymphoma

Article	Year
Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma. Bone marrow transplantation, 2022, Volume: 57, Issue:7 Topics: Aged; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Vidarabine	2022